Highlights

  • Sigma Healthcare Limited (ASX:SIG) reported FY26 Revenue of AUD 10.8 billion.
  • Normalised EBIT increased 20.6% to AUD 1.09 billion.
  • Normalised net profit after tax reached AUD 732.3 million.
  • FY26 integration synergies totalled AUD 32.6 million.

Sigma Healthcare Limited operates pharmacy retail, distribution and associated healthcare businesses across Australia and international markets. Its ASX-listed shares (ASX:SIG) traded at AUD 2.88 on November 17, 2026, a decline of 0.69% for the session. Its FY26 accounts and subsequent retail expansion update illustrate the early operating position of the merged Sigma and Chemist Warehouse businesses.

Pharmacy Retail and Distribution Footprint

Sigma Healthcare operates a pharmacy-focused Business spanning retail networks, distribution and associated services. Its combination with Chemist Warehouse Group brought branded pharmacy retail operations and wholesale capabilities together. The FY26 reporting period was its first full financial year following the merger, making integration progress and segment contributions central to its financial narrative.

Merger Integration and Network Expansion

Sigma's August 2026 results highlighted further pharmacy-network expansion and progress combining business processes. The company disclosed AUD 32.6 million of integration synergies in FY26 and maintained its target of AUD 100 million in annual synergies by FY29. That longer-term figure is a company target rather than savings already realised.

In November 2026, the company reported the opening of its first English store in Harrow, London, marking a further step in international retail expansion. Additional stores entail implementation, operating and customer-acquisition requirements, and the financial effects will depend on future reporting. Sigma Healthcare Limited (ASX:SIG) also continues to report on integration and network trading through investor announcements.

FY26 Earnings and Regional Performance

For the year ended June 30, 2026, revenue of AUD 10.8 billion was 15.5% higher than the normalised pro-forma comparative period. Normalised earnings before interest and tax were AUD 1,090.0 million, an increase of 20.6%, while the corresponding Margin reached 10.1%. Normalised net profit after tax was AUD 732.3 million, up 22.3% on the same comparative basis.

Australian segment revenue rose 14.9% and normalised EBIT increased 18.3%. International segment EBIT climbed 91.3% to AUD 55.8 million, with Ireland recording profitability for the first time according to the company's FY26 release. These figures should be read with the stated normalised pro-forma comparative methodology rather than treated as unadjusted merger-year comparisons.

Net Debt was AUD 663 million, and debt divided by normalised EBITDA stood at 0.57 times. The figures provide context for financing capacity while integration and expansion continue. Sigma Healthcare Limited (ASX:SIG) will need to maintain clear reporting on both cash requirements and the earnings contributions from established and developing markets.

Operating Environment and Strategic Priorities

Pharmacy retailers and wholesalers operate with exposure to consumer demand, medicine Supply arrangements, logistics, staffing costs and regulatory settings. Scale and network development are relevant, but they do not eliminate costs associated with systems integration or expanding into new countries. The company has identified synergy delivery as a measurable component of its post-merger strategy.

The FY26 results also showed that revenue growth and earnings growth were not identical across segments. For Sigma Healthcare Limited (ASX:SIG), future trading updates may therefore be assessed through like-for-like pharmacy activity, new store development, gross margin, normalised profitability and the pace at which integration savings are realised.

Risks and What to Monitor

Integration programmes can involve systems changes, operational complexity and expenditure before savings are fully recognised. Competitive pharmacy pricing, supply conditions and consumer spending also affect the operating environment. Expansion into international markets brings different local rules and cost structures, and planned annual synergies remain subject to implementation.

Key Insights

Sigma's first full post-merger year included higher revenue, higher normalised earnings and reported synergy savings. Australian operations remained the largest earnings context, while international activity contributed an increased EBIT result. The next reporting periods will provide a clearer measure of integration costs, expansion and debt management.